G1 Therapeutics, Inc. (GTHX) - Quarterly EPS earnings growth

Official company branding of G1 Therapeutics Inc. (GTHX)

G1 Therapeutics, Inc. (GTHX) is optimizing hospital supply chains in preparation for a merger with a global pharma behemoth to scale its developments. The quarterly EPS dynamics captured on the GURU.Markets chart demonstrate a fundamental trend, where -172.80 represents the current level of the metric. Business revenues are based on the sale of the drug Cosela for the protection of bone marrow in lung cancer patients.

G1 Therapeutics (GTHX) Earnings per share growth in annualized terms for the last twelve months: for the period 07/04/2022 - 09/28/2024

Analytical breakdowns for G1 Therapeutics, Inc.

- market value and analyst target forecast:
Fundamental company analysis:G1 Therapeutics Inc., GTHX
Manufactured product of G1 Therapeutics, Inc.

For G1 Therapeutics, Inc. (GTHX), the transition to licensing royalties and portfolio diversification makes net income dynamics a key indicator of the business model transformation's effectiveness. By analyzing the history of quarterly EPS growth, investors assess the rate of change in earnings per share, where the absence of a pronounced upward momentum in the calculations signals capital stagnation and high speculative risks.

Analysis of competing companies

Incyte Corporation (INCY) - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share growth for the last 12 months HUTCHMED Corp|NUVB (nuvationbio.com) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months dayonebio.com (DAWN)|Year-over-year earnings per share growth for the last twelve months Monopar Corp (MNPR)|INBX - Earnings per share growth in annualized terms for the last twelve months|Year-over-year earnings per share growth for the last twelve months I-Mab Inc. IMAB|Fennec - Year-over-year earnings per share growth for the last twelve months|HRTX - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Nuvectis Pharma, Inc.|CHRS: Quarterly EPS earnings growth|Net earnings per share growth for the trailing year Corbus Pharma CRBP|Year-over-year net earnings per share growth for the last 12 months CRDF|Earnings per share growth in annualized terms for the last twelve months BeyondSpring Inc. BYSI|Year-over-year net earnings per share growth for the last 12 months BCAB (BioAtla Inc)|LIXT (Lixte Biotechnology Holdings, Inc.) - Year-over-year earnings per one share growth for the last 12 months|Citius Pharmaceuticals, Inc. - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months CLRB (Cellectar Biosciences, Inc.)|BioLineRx Corp - Quarterly EPS earnings growth|Year-over-year earnings per one share growth for the last 12 months CANF (Can-Fite BioPharma, Ltd.)|APRE: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Kazia (KZIA)|Year-over-year earnings per share growth for the last twelve months silexion.com|NCNA: Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth CMRX|Quarterly EPS earnings growth Cyclacel, Inc. (CYCC)|Year-over-year earnings per share growth for the last twelve months Kronos Bio Corp KRON|KTRA (Kintara Therapeutics, Inc.) - Year-over-year net earnings per share trend for the last twelve months|ONCT: Year-over-year net earnings per share growth for the last 12 months|Earnings per share growth in annualized terms for the last twelve months Portage Biotech Inc